WallStreetZenWallStreetZen

NASDAQ: SONN
Sonnet Biotherapeutics Holdings Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for SONN

Based on 2 analysts offering 12 month price targets for Sonnet Biotherapeutics Holdings Inc.
Min Forecast
$6.70+1,259.03%
Avg Forecast
$10.35+1,999.39%
Max Forecast
$14.00+2,739.76%

Should I buy or sell SONN stock?

Based on 2 analysts offering ratings for Sonnet Biotherapeutics Holdings Inc.
Strong Buy
Strong Buy
2 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their SONN stock forecasts and price targets.

SONN stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
EF Hutton
Top 13%
88
Strong BuyAssumes$6.70+1,259.03%2023-05-25
Chardan Capital
Top 3%
98
Strong BuyMaintains$14.00+2,739.76%2023-05-11

1 of 1

Forecast return on equity

Is SONN forecast to generate an efficient return?
Company
-4,227.65%
Industry
29.69%
Market
89.37%
SONN's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is SONN forecast to generate an efficient return on assets?
Company
-1,705.08%
Industry
11.82%
SONN is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

SONN revenue growth forecast

How is SONN forecast to perform vs Biotechnology companies and vs the US market?
Company
-91.38%
Industry
64.21%
Market
8.83%
SONN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
SONN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

SONN vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
SONN$0.49$10.35+1,999.39%Strong Buy
FREQ$0.38$4.00+952.63%Buy
NRBO$0.50N/AN/A
ACGN$1.63N/AN/A
TPST$1.19$18.33+1,440.59%Strong Buy
View Top Biotech Stocks

Sonnet Biotherapeutics Holdings Stock Forecast FAQ

Is Sonnet Biotherapeutics Holdings Stock a good buy in 2023, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: SONN) stock is to Strong Buy SONN stock.

Out of 2 analysts, 2 (100%) are recommending SONN as a Strong Buy, 0 (0%) are recommending SONN as a Buy, 0 (0%) are recommending SONN as a Hold, 0 (0%) are recommending SONN as a Sell, and 0 (0%) are recommending SONN as a Strong Sell.

If you're new to stock investing, here's how to buy Sonnet Biotherapeutics Holdings stock.

What is SONN's forecast return on equity (ROE) for 2023-2025?

(NASDAQ: SONN) forecast ROE is -4,227.65%, which is considered weak.

What is SONN's Price Target?

According to 2 Wall Street analysts that have issued a 1 year SONN price target, the average SONN price target is $10.35, with the highest SONN stock price forecast at $14.00 and the lowest SONN stock price forecast at $6.70.

On average, Wall Street analysts predict that Sonnet Biotherapeutics Holdings's share price could reach $10.35 by May 25, 2024. The average Sonnet Biotherapeutics Holdings stock price prediction forecasts a potential upside of 1,999.39% from the current SONN share price of $0.49.

What is SONN's forecast return on assets (ROA) for 2023-2025?

(NASDAQ: SONN) forecast ROA is -1,705.08%, which is lower than the forecast US Biotechnology industry average of 11.82%.
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTube
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.